Infliximab therapy in an infant with Netherton syndrome.

Cicek F., Cekic Ş., Kilic S. Ş.

Pediatric dermatology, cilt.38, sa.3, ss.714-716, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 38 Sayı: 3
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1111/pde.14590
  • Dergi Adı: Pediatric dermatology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.714-716
  • Anahtar Kelimeler: childhood, ichthyosis, &#305, nfliximab, Netherton Syndrome, tumor necrosis factor&#8208, a
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

We present a patient with Netherton syndrome and severe skin manifestations treated with infliximab. By 6 months of age, the child had intractable pruritus, scaling, dry skin, and generalized eczematous lesions resistant to conventional therapies for atopic dermatitis. Clinical improvement was observed following the third infusion of infliximab, and by 12 months of age, the skin lesions completely resolved. Infliximab is a promising option for the management of skin inflammation in Netherton syndrome, even in infants.